The Bio-Techne Corp has experienced a turbulent period, facing multiple headwinds in Q1 and seeing a decline in stock despite satisfactory financials. However, analysts have set a price target at $81.00, suggesting the market could correct the share price. The company declared a dividend and even highlighted top-line biomarker data produced in collaboration with Regulus Therapeutics. A new distribution agreement with Thermo Fisher Scientific has been announced and they have achieved over 10,000 peer-reviewed publications citing their RNAscope technology. The stocks are seen as undervalued, with intrinsic value estimated to be 32% higher than their current value. Despite weak Q4 results, promising Q3 earnings have been revealed. Bio-Techne plans to present at multiple upcoming investor conferences and has recently appointed Kim Kelderman as CEO. Their noteworthy activities include a successfully filed lawsuit against Molecular Instruments for patent infringement, along with receiving several awards and certifications. Cutting edge progress is highlighted by Bio-Techne through the launch of their first automated, multiomics application, which revolutionizes spatial biology research. A strategic partnership with Nikon Instruments Inc. is expanding access to innovative spatial biology services. Comparatively, the company's shares have been purchased and sold by notable investment firms.
Bio-Techne Corp TECH News Analytics from Wed, 04 May 2016 07:00:00 GMT to Thu, 04 Jul 2024 10:51:52 GMT -
Rating 2
- Innovation 5
- Information 7
- Rumor -1
